-
Something wrong with this record ?
Long-Term Efficacy, Safety, and Drug Survival of Guselkumab in Patients with Psoriasis: Real-World Data from the Czech Republic BIOREP Registry
J. Hugo, M. Kojanova, B. Turkova, S. Gkalpakiotis, BIOREP Study Group
Status not-indexed Language English Country Switzerland
Document type Journal Article
NLK
Directory of Open Access Journals
from 2011
Free Medical Journals
from 2011
PubMed Central
from 2011
Europe PubMed Central
from 2011
ProQuest Central
from 2011-09-01
Open Access Digital Library
from 2011-01-01
Open Access Digital Library
from 2011-01-01
Health & Medicine (ProQuest)
from 2011-09-01
ROAD: Directory of Open Access Scholarly Resources
from 2011
Springer Journals Complete - Open Access
from 2011-09-01
Springer Nature OA/Free Journals
from 2011-09-01
- Publication type
- Journal Article MeSH
BACKGROUND: Real-world data on the long-term use of guselkumab for treatment of psoriasis are still limited. OBJECTIVE: We aimed to evaluate long-term efficacy, safety, and drug survival of guselkumab in a real-world setting. METHODS: This is a retrospective study analyzing Czech Republic registry (BIOREP) data of patients treated with guselkumab. RESULTS: In total, 333 patients were included. Improvement in Psoriasis Area and Severity Index (PASI) score was significant. Mean PASI score decreased from 16 at baseline to 0.7, 0.9, and 0.8 after 12, 24, and 36 months, respectively. Absolute PASI scores of ≤ 3 and ≤ 1 were achieved in 93.9% and 77.9%, 94.2% and 71.0%, and 94.8% and 70.7% of patients after 12, 24, and 36 months, respectively. Response PASI 90 and PASI 100 were attained in 81.8% and 57.1%, 75.4% and 50.7%, and 75.9% and 55.2% of patients after 12, 24, and 36 months, respectively. The percentage of patients achieving PASI 90 and PASI 100 responses was higher throughout the study in bio-naive and in normal-weight patients, while presence of psoriatic arthritis had no influence. Improvement in Dermatology Life Quality Index (DLQI) score was also significant; mean DLQI score decreased from 14.2 at baseline to 0.9, 1.0, and 0.7 after 12, 24, and 36 months, respectively. Patients with PASI 100 had lower mean DLQI throughout the study compared with patients with PASI 90. Major reason for discontinuation was loss of effectiveness in 7.1% of patients, while only 0.6% were due to adverse events. Overall cumulative drug survival was high, with only a minimal decline over time, reaching 91.6%, 87.0%, and 85.5% after 12, 24, and 36 months, respectively. Drug survival was not affected by previous biological treatment, patient weight, or presence of psoriatic arthritis. CONCLUSIONS: This real-world study demonstrated the long-term effectiveness, good safety profile, and high drug survival of guselkumab treatment over a period of 36 months.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23002795
- 003
- CZ-PrNML
- 005
- 20230421100139.0
- 007
- ta
- 008
- 230413s2023 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s13555-023-00893-4 $2 doi
- 035 __
- $a (PubMed)36723775
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Hugo, Jan $u Department of Dermatovenereology, Third Faculty of Medicine, Charles University and University Hospital Kralovske Vinohrady, Prague, Czech Republic. jan.hugo@fnkv.cz $1 https://orcid.org/0000000243413812
- 245 10
- $a Long-Term Efficacy, Safety, and Drug Survival of Guselkumab in Patients with Psoriasis: Real-World Data from the Czech Republic BIOREP Registry / $c J. Hugo, M. Kojanova, B. Turkova, S. Gkalpakiotis, BIOREP Study Group
- 520 9_
- $a BACKGROUND: Real-world data on the long-term use of guselkumab for treatment of psoriasis are still limited. OBJECTIVE: We aimed to evaluate long-term efficacy, safety, and drug survival of guselkumab in a real-world setting. METHODS: This is a retrospective study analyzing Czech Republic registry (BIOREP) data of patients treated with guselkumab. RESULTS: In total, 333 patients were included. Improvement in Psoriasis Area and Severity Index (PASI) score was significant. Mean PASI score decreased from 16 at baseline to 0.7, 0.9, and 0.8 after 12, 24, and 36 months, respectively. Absolute PASI scores of ≤ 3 and ≤ 1 were achieved in 93.9% and 77.9%, 94.2% and 71.0%, and 94.8% and 70.7% of patients after 12, 24, and 36 months, respectively. Response PASI 90 and PASI 100 were attained in 81.8% and 57.1%, 75.4% and 50.7%, and 75.9% and 55.2% of patients after 12, 24, and 36 months, respectively. The percentage of patients achieving PASI 90 and PASI 100 responses was higher throughout the study in bio-naive and in normal-weight patients, while presence of psoriatic arthritis had no influence. Improvement in Dermatology Life Quality Index (DLQI) score was also significant; mean DLQI score decreased from 14.2 at baseline to 0.9, 1.0, and 0.7 after 12, 24, and 36 months, respectively. Patients with PASI 100 had lower mean DLQI throughout the study compared with patients with PASI 90. Major reason for discontinuation was loss of effectiveness in 7.1% of patients, while only 0.6% were due to adverse events. Overall cumulative drug survival was high, with only a minimal decline over time, reaching 91.6%, 87.0%, and 85.5% after 12, 24, and 36 months, respectively. Drug survival was not affected by previous biological treatment, patient weight, or presence of psoriatic arthritis. CONCLUSIONS: This real-world study demonstrated the long-term effectiveness, good safety profile, and high drug survival of guselkumab treatment over a period of 36 months.
- 590 __
- $a NEINDEXOVÁNO
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Kojanova, Martina $u Department of Dermatovenereology, First Faculty of Medicine and General University Hospital, Charles University, Prague, Czech Republic
- 700 1_
- $a Turkova, Barbora $u Value Outcomes, Prague, Czech Republic
- 700 1_
- $a Gkalpakiotis, Spyridon $u Department of Dermatovenereology, Third Faculty of Medicine, Charles University and University Hospital Kralovske Vinohrady, Prague, Czech Republic
- 710 2_
- $a BIOREP Study Group
- 773 0_
- $w MED00207103 $t Dermatology and therapy $x 2193-8210 $g Roč. 13, č. 3 (2023), s. 787-801
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/36723775 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230413 $b ABA008
- 991 __
- $a 20230421100131 $b ABA008
- 999 __
- $a ok $b bmc $g 1922672 $s 1189002
- BAS __
- $a 3
- BAS __
- $a PreBMC-PubMed-not-MEDLINE
- BMC __
- $a 2023 $b 13 $c 3 $d 787-801 $e 20230201 $i 2193-8210 $m Dermatology and therapy $n Dermatol Ther (Heidelb) $x MED00207103
- LZP __
- $a Pubmed-20230413
